
Sign up to save your podcasts
Or


This episode exposes how pharmaceutical giants profit from sickness by controlling drug patents, inflating prices, and prioritizing marketing over medical ethics. It explains how taxpayer-funded research is often privatized for corporate gain, and how monopolies prevent access to affordable treatment. Using the opioid crisis as a case study, the episode highlights how profit-driven strategies can lead to mass harm. Ultimately, it argues that healthcare has become a business first and a service second—and questions whether life-saving medicine should belong in the hands of private corporations.
By Scott CarrickThis episode exposes how pharmaceutical giants profit from sickness by controlling drug patents, inflating prices, and prioritizing marketing over medical ethics. It explains how taxpayer-funded research is often privatized for corporate gain, and how monopolies prevent access to affordable treatment. Using the opioid crisis as a case study, the episode highlights how profit-driven strategies can lead to mass harm. Ultimately, it argues that healthcare has become a business first and a service second—and questions whether life-saving medicine should belong in the hands of private corporations.